12:00 AM
 | 
May 14, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Latuda lurasidone: Additional Phase III data

Additional data from the double-blind, international Phase III PREVAIL 1 trial in 348 patients with bipolar I depression showed that once-daily 20-120 mg Latuda as an add-on to lithium or valproate significantly reduced MADRS scores from baseline to week 6, the primary endpoint, by 17.1 points vs. 13.5 points for placebo (p<0.01). On secondary endpoints, Latuda significantly reduced CGI-BP-S and HAM-A scores from baseline to week 6 by 2 and 8 points, respectively, vs. 1.5 and 6 points for placebo (p<0.01 for both)....

Read the full 392 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >